BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 14, 2005
View Archived Issues
Vertex, GSK In Potential $405M VX-409 Preclinical Collaboration
Partnering a promising preclinical pain product, Vertex Pharmaceuticals Inc. granted GlaxoSmithKline plc worldwide development and commercialization rights in a deal worth up to $405 million plus royalties. (BioWorld Today)
Read More
Insmed's iPlex: Second Orphan Drug Approved In Short Stature
Read More
Missed Phase II Velafermin Endpoint Drops CuraGen
Read More
Halozyme's Stock Sale Raising $16.1M After Nod For Hylenex
Read More
Other News To Note
Read More
ASH Roundup
Read More